{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insulin-therapy-in-type-1-diabetes/goals-outcome-measures/qipp-options-for-local-implementation/","result":{"pageContext":{"chapter":{"id":"2dc6198c-0433-5023-aa1b-6862a4d3ed59","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation","depth":2,"htmlHeader":"<!-- begin field 6058838a-842e-447e-bb3b-a3ad33eb9014 --><h2>QIPP - Options for local implementation</h2><!-- end field 6058838a-842e-447e-bb3b-a3ad33eb9014 -->","summary":null,"htmlStringContent":"<!-- begin item 8e4f305f-f15d-4c80-a14f-17f4f91013af --><!-- begin field 22b30081-5d94-46eb-b40c-afee77ee8306 --><div><h3>Safer insulin prescribing</h3><ul><li>Be aware of the differences between insulin products and ensure that people receive appropriate training on their correct use. Advise people to only use insulin in the way they have been trained because using it any other way may result in a dangerous overdose or underdose.</li><li>Ensure that people with diabetes who are receiving insulin therapy are given information about awareness and management of hypoglycaemia.</li><li>Ensure that people with diabetes who use insulin and who drive are aware of the need to notify the Driver and Vehicle Licensing Agency (DVLA). Healthcare professionals should refer to chapter 3 of the DVLA's <a href=\"https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals\" target=\"_top\" data-hyperlink-id=\"d6768ca9-f2d6-4a96-aaef-abe60116937d\">Assessing fitness to drive: a guide for healthcare professionals</a> for more information.</li><li>Be aware of 'sick-day' rules and ensure that people with diabetes who are receiving insulin therapy are given appropriate information about these.</li><li>Give adults who are using insulin therapy a patient information booklet and an Insulin Passport.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/insulin-therapy-in-type-1-diabetes/references/\">NICE, 2019</a>]</p></div><!-- end field 22b30081-5d94-46eb-b40c-afee77ee8306 --><!-- end item 8e4f305f-f15d-4c80-a14f-17f4f91013af -->","topic":{"id":"418fc016-0e56-5e3b-b2ea-3927d2911520","topicId":"fea45be3-7039-4e82-a497-8f104e2219fa","topicName":"Insulin therapy in type 1 diabetes","slug":"insulin-therapy-in-type-1-diabetes","lastRevised":"Last revised in July 2020","chapters":[{"id":"954264ab-b538-5bf1-97b7-0f924f8d8cf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3ff43781-7d14-5b7f-afad-bdf21a03a066","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2847fe29-3881-5cdb-a7bc-46613048cf07","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cca9cb48-98c0-532b-be68-7babcbefb124","slug":"changes","fullItemName":"Changes"},{"id":"d93b8dec-544f-532d-902d-66e613ea505d","slug":"update","fullItemName":"Update"}]},{"id":"ec62a12c-2df5-5ba3-83ae-04575a5df833","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bea46ae9-5b5d-5501-8642-95bebd864aa1","slug":"goals","fullItemName":"Goals"},{"id":"637cdedd-d944-52d1-9428-f71dedd59179","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecc1db03-98d4-5682-a7a3-7d52d3da9b84","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ef866cac-6d08-5a10-a858-cbbf60d218e6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2dc6198c-0433-5023-aa1b-6862a4d3ed59","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a289174b-e042-5fce-924a-1f34b54849a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bad524b5-e1b5-52b0-aa55-2cc89cb11660","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"457536b7-af83-548a-b54e-8d0edaeafd3f","slug":"what-is-insulin","fullItemName":"What is insulin?"}]},{"id":"e457b08c-e5c6-5790-ba8c-f88e071da0b0","fullItemName":"Management","slug":"management","subChapters":[{"id":"676c7992-874b-537d-8c19-1f2960b3cc32","slug":"insulin-therapy-type-1-diabetes","fullItemName":"Scenario: Insulin therapy - type 1 diabetes"}]},{"id":"4beb3cd5-7f83-5f1c-9623-cc5e61eae703","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5da0d096-2a12-5776-bc2b-bd37233342e8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8863b2a8-ba84-522f-8b51-20da713ec903","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b16eeb02-30c3-54db-ad00-8543e4b4cef6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"452ae6ee-2e11-57b1-bbed-4515efd11fc8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ead30a9a-3f18-5514-8a77-69d9bf069d3c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d600b94-edf3-51e4-85d9-72002fbf5fc5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6648325a-6d11-5ed7-9bb9-aff9e9d4ee55","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ec62a12c-2df5-5ba3-83ae-04575a5df833","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}